Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease

Phase 1 Recruiting 40 enrolled AstraZeneca

RandomizedParallel-groupQuadruple-blindTreatment

Summary

A study to investigate safety, tolerability, and pharmacokinetics of AZD1613 following subcutaneous or intravenous administration in participants with autosomal dominant polycystic kidney disease (ADPKD).

Timeline

Start: 2025-11-10
Primary completion: 2027-01-26
Completion: 2027-01-26

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AZD1613	Unknown	—	Subcutaneous

Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease

Summary

Timeline

Drugs

Indications